COSM Cosmos Health Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 1474167 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY33.8%
TTM net income YoY-13.1%
TTM EPS YoY35.6%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—
Margins
Gross margin10.3%
Operating margin-24.9%
Net margin-33.1%
FCF margin-13.5%
EBITDA margin-23.0%
Returns
ROE-104.0%
ROA-39.6%
ROIC (approx.)-54.8%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity0.15x
Current ratio1.05x
Interest coverage-7.80x
Cash quality & payout
Operating cash flow / net income0.40x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $65.27M | $54.43M |
| Cost of revenue | $57.38M | $50.12M |
| Gross profit | $7.90M | $4.31M |
| R&D expense | $519,363 | $533,293 |
| SG&A expense | $15.62M | $11.73M |
| Operating income | -$16.70M | -$15.54M |
| Interest expense | $1.90M | $1.01M |
| Pretax income | -$19.14M | -$16.18M |
| Income tax | $0 | $0 |
| Net income | -$19.14M | -$16.18M |
| EBITDA | -$15.34M | -$14.33M |
| EPS (basic) | -0.63 | -1.17 |
| EPS (diluted) | -0.63 | -1.17 |
| Weighted avg. shares (diluted) | 30.29M | 19.15M |
| Balance sheet | ||
| Cash & equivalents | $715,674 | $315,105 |
| Short-term investments | $46,158 | $21,148 |
| Receivables | $19.63M | $13.48M |
| Inventory | $5.78M | $4.36M |
| Current assets | $38.39M | $25.46M |
| PP&E, net | $10.58M | $9.69M |
| Goodwill | $49,697 | $49,697 |
| Intangibles | $7.52M | $7.71M |
| Total assets | $65.48M | $54.31M |
| Current liabilities | $38.27M | $25.76M |
| Long-term debt | $3.78M | $4.11M |
| Total debt | $3.78M | $4.11M |
| Total liabilities | $47.05M | $29.78M |
| Shareholders' equity | $18.42M | $24.53M |
| Net debt | $3.06M | $3.79M |
| Shares outstanding | 41.07M | 23.60M |
| Cash flow statement | ||
| Operating cash flow | -$8.45M | -$7.72M |
| Capital expenditure | $55,675 | $418,075 |
| Free cash flow | -$8.50M | -$8.14M |
| Investing cash flow | -$2.01M | -$798,269 |
| Financing cash flow | $14.06M | $5.05M |
| Depreciation & amortization | $1.36M | $1.22M |
| Stock-based compensation | $2.31M | $1.69M |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.